Company profile
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PERAMIVIR | approved | — | 10 | approved |
| AVORALSTAT | phase2_3 | — | 4 | no active trials |
| Berotralstat | phase2_3 | — | 7 | no active trials |
| ULODESINE | phase2 | — | 2 | no active trials |
| FORODESINE | phase1_2 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (53)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02303626 | phase2_3 | completed | 2014-12-17 | 2016-01-01 | BioCryst Pharmaceuticals | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks |
| NCT03136237 | phase1 | completed | 2017-02-17 | 2017-08-15 | BioCryst Pharmaceuticals | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions |
| NCT03472040 | phase2_3 | completed | 2018-02-16 | 2022-04-27 | BioCryst Pharmaceuticals | A Long Term Safety Study of BCX7353 in Hereditary Angioedema |
| NCT04702568 | phase2 | terminated | 2020-12-18 | 2023-10-04 | BioCryst Pharmaceuticals | A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| NCT02319772 | phase1 | completed | 2014-12-01 | 2016-03-01 | BioCryst Pharmaceuticals | A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 |
FDA applications (3)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 206426 | NDA | BIOCRYST PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 214094 | NDA | BIOCRYST PHARMACEUTICALS INC | ||||
Loading… | ||||||
| NDA 219776 | NDA | BIOCRYST PHARMACEUTICALS INC | ||||
Loading… | ||||||